SEC Filing Summary: Cody Resources, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cody Resources, Inc., a Nevada corporation, with a report date of May 21, 2008. The filing discloses the entry into a Material Definitive Agreement regarding a corporate merger. Note: The metadata provided in the request lists the company as "Niagen Bioscience, Inc."; however, the filing text explicitly identifies the registrant as Cody Resources, Inc., which is entering into a merger with ChromaDex, Inc.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Transaction Details
- Merger Agreement: On May 21, 2008, Cody Resources, Inc. (the "Issuer") entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, CDI Acquisition, Inc. ("CDI"), and ChromaDex, Inc. ("ChromaDex").
- Structure: CDI will merge with and into ChromaDex, with ChromaDex surviving as the corporation.
- Exchange Ratio: Each share of ChromaDex common stock will be exchanged for one share of Cody Resources common stock (1:1 ratio).
- Derivatives: Outstanding rights, options, and warrants of ChromaDex will convert to equivalent instruments for Cody Resources stock on the same terms.
- Corporate Restructuring: Prior to the merger completion, the Issuer plans to merge into a new Delaware subsidiary to change its domicile and rename itself "ChromaDex Corporation."
Conditions, Risks, and Outlook
- Approval Requirement: The completion of the Merger is conditioned on the consent of holders of at least 99% of the outstanding common stock of ChromaDex.
- Documentation: The full terms are detailed in the Merger Agreement attached as Exhibit 10.1.
- Management Commentary: The filing contains no specific management commentary on future financial outlook or risks beyond the transaction conditions.
Investor Verification Checklist
- Verify the 1:1 exchange ratio and the treatment of existing ChromaDex options and warrants.
- Confirm the status of the 99% shareholder consent requirement for ChromaDex.
- Review the full text of the Merger Agreement (Exhibit 10.1) for additional covenants or termination rights.
- Monitor the timeline for the domicile change from Nevada to Delaware and the name change to ChromaDex Corporation.
- Clarify the discrepancy between the request metadata ("Niagen Bioscience") and the filing registrant ("Cody Resources").